ECPG:NASDAQEncore Capital Group Inc Analysis
Data as of 2026-06-18 - not real-time
$82.64
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Encore Capital Group trades around $82.6, just below its 20‑day SMA of $80.8 and well above the 200‑day SMA of $60.5, indicating a long‑term uptrend. The MACD histogram is positive (0.23) and the MACD line sits above its signal, a bullish technical signal. RSI at 56 suggests the stock is neither overbought nor oversold, supporting a neutral short‑term bias. Volume is increasing, and the price is holding above the identified support of $77.0 while approaching resistance near $85.3. Fundamentally, the company posts a trailing P/E of 6.4 versus an industry average of 17, and a forward P/E of 6.2, highlighting deep value relative to peers. However, the DCF‑derived fair value of $16.4 is far below the current market price, implying a substantial overvaluation gap of over 400%. The balance sheet shows a debt‑to‑equity ratio of 390%, with total debt exceeding $4 billion, creating leverage concerns. Operating cash flow is positive ($190 M) but free cash flow is negative, reflecting ongoing investment or debt service pressures.
Recent earnings beat, with collections up 20% YoY and EPS of $10.91, plus guidance for 10% EPS growth in 2026, underscores strong operational performance. Insider activity includes a notable sell by SVP Andrew Asch on June 11, which could temper short‑term sentiment. The Fear & Greed Index reads “Extreme Greed,” indicating market enthusiasm that may be detached from fundamentals. Given the low beta (≈0.84) the stock is less volatile than the market, yet 30‑day volatility sits at 27%, suggesting price swings. The overall upside potential per the model is ~34%, but the downside risk is limited by the support level and strong earnings momentum. In this context, the stock presents a mixed picture: attractive earnings and valuation metrics offset by heavy leverage and an inflated market price.
Recent earnings beat, with collections up 20% YoY and EPS of $10.91, plus guidance for 10% EPS growth in 2026, underscores strong operational performance. Insider activity includes a notable sell by SVP Andrew Asch on June 11, which could temper short‑term sentiment. The Fear & Greed Index reads “Extreme Greed,” indicating market enthusiasm that may be detached from fundamentals. Given the low beta (≈0.84) the stock is less volatile than the market, yet 30‑day volatility sits at 27%, suggesting price swings. The overall upside potential per the model is ~34%, but the downside risk is limited by the support level and strong earnings momentum. In this context, the stock presents a mixed picture: attractive earnings and valuation metrics offset by heavy leverage and an inflated market price.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and rising volume suggest momentum
- Price near support with room to test resistance
- Insider sell may create short‑term buying opportunity
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Low P/E relative to industry indicates value potential
- Strong earnings growth and collection performance
- Heavy leverage and negative free cash flow limit upside
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High debt‑to‑equity ratio poses balance‑sheet risk
- Sustainable operating margins but limited cash generation
- Market price far above DCF fair value suggesting valuation correction
Key Metrics & Analysis
Financial Health
Revenue Growth21.00%
Profit Margin16.00%
P/E Ratio6.4
ROE31.96%
ROA8.17%
Debt/Equity390.51
P/B Ratio1.7
Op. Cash Flow$190.2M
Free Cash Flow$-229486752
Industry P/E17.1
Technical Analysis
TrendNeutral
RSI56.5
Support$77.02
Resistance$85.35
MA 20$80.79
MA 50$81.11
MA 200$60.49
MACDBullish
VolumeIncreasing
Fear & Greed Index88.5
Valuation
Fair Value$16.38
Target Price$111.00
Upside/Downside34.32%
GradeOvervalued
TypeValue
Risk Assessment
Beta0.84
Volatility27.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.